Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis

Hernan Nicolas Lemus, Arthur E. Warrington, Aleksandar Denic, Bharath Wootla, Moses Rodriguez

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A single peripheral dose of CNS-binding IgMs promote remyelination and preserve axons in a number of animal models of neurologic disease. A myelin-binding recombinant human IgM (rHIgM22) is presently in a safety trial in MS patients following an acute MS exacerbation. rHIgM22 (directed against oligodendrocytes) or rHIgM12 (directed against neurons) were administered to mice with MOG-induced experimental autoimmune encephalomyelitis (EAE) with study endpoints: Clinical deficits and brain and spinal cord pathology. IgMs were administered at a therapeutic dose of 100 μg intra peritoneal at the time of immunization (day-1, 0, +1), disease onset (15 days) or peak of the disease (28 days). Disease course was not worsened by either human IgM regardless of the time of treatment. Of note, the human IgM that recognizes a carbohydrate epitope on gangliosides and NCAM, rHIgM12, reduced brain pathology when given at time of immunization or at onset of disease, but did not reduce clinical deficits or spinal cord disease burden. Hence, treatment with rHIgM12 resulted in marked reduction in meningeal inflammation. Data consistent with the hypothesis that in the EAE model this molecule has an immune-modulatory effect. Treatment with an anti-CD4 blocking IgG prevented both clinical course and CNS pathology. This pre-clinical study further supports the safety of therapeutic CNS-binding human IgMs in the presence of autoimmunity and clearly differentiates them from IgGs directed against MOG or aquaporin-4 that worsen neurologic disease.

Original languageEnglish (US)
Pages (from-to)121-129
Number of pages9
JournalHuman Antibodies
Volume25
Issue number3-4
DOIs
StatePublished - Apr 24 2017

Fingerprint

Autoimmune Experimental Encephalomyelitis
Immunoglobulin M
Pathology
Brain
Nervous System Diseases
CD4 Immunoadhesins
Immunization
Aquaporin 4
Therapeutics
Safety
Neural Cell Adhesion Molecules
Gangliosides
Spinal Cord Diseases
Oligodendroglia
Myelin Sheath
Autoimmunity
Axons
Epitopes
Spinal Cord
Animal Models

Keywords

  • Experimental autoimmune encephalomyelitis
  • Human antibody
  • Inflammation
  • Myelin oligodendrocyte glycoprotein

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis. / Lemus, Hernan Nicolas; Warrington, Arthur E.; Denic, Aleksandar; Wootla, Bharath; Rodriguez, Moses.

In: Human Antibodies, Vol. 25, No. 3-4, 24.04.2017, p. 121-129.

Research output: Contribution to journalArticle

Lemus, Hernan Nicolas ; Warrington, Arthur E. ; Denic, Aleksandar ; Wootla, Bharath ; Rodriguez, Moses. / Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis. In: Human Antibodies. 2017 ; Vol. 25, No. 3-4. pp. 121-129.
@article{30af14790f4d4897ad305680aa0a2a7a,
title = "Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis",
abstract = "A single peripheral dose of CNS-binding IgMs promote remyelination and preserve axons in a number of animal models of neurologic disease. A myelin-binding recombinant human IgM (rHIgM22) is presently in a safety trial in MS patients following an acute MS exacerbation. rHIgM22 (directed against oligodendrocytes) or rHIgM12 (directed against neurons) were administered to mice with MOG-induced experimental autoimmune encephalomyelitis (EAE) with study endpoints: Clinical deficits and brain and spinal cord pathology. IgMs were administered at a therapeutic dose of 100 μg intra peritoneal at the time of immunization (day-1, 0, +1), disease onset (15 days) or peak of the disease (28 days). Disease course was not worsened by either human IgM regardless of the time of treatment. Of note, the human IgM that recognizes a carbohydrate epitope on gangliosides and NCAM, rHIgM12, reduced brain pathology when given at time of immunization or at onset of disease, but did not reduce clinical deficits or spinal cord disease burden. Hence, treatment with rHIgM12 resulted in marked reduction in meningeal inflammation. Data consistent with the hypothesis that in the EAE model this molecule has an immune-modulatory effect. Treatment with an anti-CD4 blocking IgG prevented both clinical course and CNS pathology. This pre-clinical study further supports the safety of therapeutic CNS-binding human IgMs in the presence of autoimmunity and clearly differentiates them from IgGs directed against MOG or aquaporin-4 that worsen neurologic disease.",
keywords = "Experimental autoimmune encephalomyelitis, Human antibody, Inflammation, Myelin oligodendrocyte glycoprotein",
author = "Lemus, {Hernan Nicolas} and Warrington, {Arthur E.} and Aleksandar Denic and Bharath Wootla and Moses Rodriguez",
year = "2017",
month = "4",
day = "24",
doi = "10.3233/HAB-170313",
language = "English (US)",
volume = "25",
pages = "121--129",
journal = "Human Antibodies",
issn = "1093-2607",
publisher = "IOS Press",
number = "3-4",

}

TY - JOUR

T1 - Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis

AU - Lemus, Hernan Nicolas

AU - Warrington, Arthur E.

AU - Denic, Aleksandar

AU - Wootla, Bharath

AU - Rodriguez, Moses

PY - 2017/4/24

Y1 - 2017/4/24

N2 - A single peripheral dose of CNS-binding IgMs promote remyelination and preserve axons in a number of animal models of neurologic disease. A myelin-binding recombinant human IgM (rHIgM22) is presently in a safety trial in MS patients following an acute MS exacerbation. rHIgM22 (directed against oligodendrocytes) or rHIgM12 (directed against neurons) were administered to mice with MOG-induced experimental autoimmune encephalomyelitis (EAE) with study endpoints: Clinical deficits and brain and spinal cord pathology. IgMs were administered at a therapeutic dose of 100 μg intra peritoneal at the time of immunization (day-1, 0, +1), disease onset (15 days) or peak of the disease (28 days). Disease course was not worsened by either human IgM regardless of the time of treatment. Of note, the human IgM that recognizes a carbohydrate epitope on gangliosides and NCAM, rHIgM12, reduced brain pathology when given at time of immunization or at onset of disease, but did not reduce clinical deficits or spinal cord disease burden. Hence, treatment with rHIgM12 resulted in marked reduction in meningeal inflammation. Data consistent with the hypothesis that in the EAE model this molecule has an immune-modulatory effect. Treatment with an anti-CD4 blocking IgG prevented both clinical course and CNS pathology. This pre-clinical study further supports the safety of therapeutic CNS-binding human IgMs in the presence of autoimmunity and clearly differentiates them from IgGs directed against MOG or aquaporin-4 that worsen neurologic disease.

AB - A single peripheral dose of CNS-binding IgMs promote remyelination and preserve axons in a number of animal models of neurologic disease. A myelin-binding recombinant human IgM (rHIgM22) is presently in a safety trial in MS patients following an acute MS exacerbation. rHIgM22 (directed against oligodendrocytes) or rHIgM12 (directed against neurons) were administered to mice with MOG-induced experimental autoimmune encephalomyelitis (EAE) with study endpoints: Clinical deficits and brain and spinal cord pathology. IgMs were administered at a therapeutic dose of 100 μg intra peritoneal at the time of immunization (day-1, 0, +1), disease onset (15 days) or peak of the disease (28 days). Disease course was not worsened by either human IgM regardless of the time of treatment. Of note, the human IgM that recognizes a carbohydrate epitope on gangliosides and NCAM, rHIgM12, reduced brain pathology when given at time of immunization or at onset of disease, but did not reduce clinical deficits or spinal cord disease burden. Hence, treatment with rHIgM12 resulted in marked reduction in meningeal inflammation. Data consistent with the hypothesis that in the EAE model this molecule has an immune-modulatory effect. Treatment with an anti-CD4 blocking IgG prevented both clinical course and CNS pathology. This pre-clinical study further supports the safety of therapeutic CNS-binding human IgMs in the presence of autoimmunity and clearly differentiates them from IgGs directed against MOG or aquaporin-4 that worsen neurologic disease.

KW - Experimental autoimmune encephalomyelitis

KW - Human antibody

KW - Inflammation

KW - Myelin oligodendrocyte glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=85018446697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018446697&partnerID=8YFLogxK

U2 - 10.3233/HAB-170313

DO - 10.3233/HAB-170313

M3 - Article

C2 - 28269761

AN - SCOPUS:85018446697

VL - 25

SP - 121

EP - 129

JO - Human Antibodies

JF - Human Antibodies

SN - 1093-2607

IS - 3-4

ER -